TY - JOUR
T1 - The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice
AU - Abe, Miyuki
AU - Funakoshi-Tago, Megumi
AU - Tago, Kenji
AU - Kamishimoto, Jun
AU - Aizu-Yokota, Eriko
AU - Sonoda, Yoshiko
AU - Kasahara, Tadashi
N1 - Funding Information:
We thank Mr. K. Sumi, J Furusawa and Mr. T. Oshio for their technical assistance. This work was supported in part by grants (19790071) from MEXT, the Research Foundation for Pharmaceutical Sciences and the Hi-Tech Research Center Project for Private Universities in Japan.
PY - 2009/7
Y1 - 2009/7
N2 - The somatic Jak2 mutation (V617F) was identified in most patients with polycythemia vera (PV). Here, we show that the activating Jak2 V617F mutant completely protected Ba/F3 cells from cytokine withdrawal-induced apoptotic cell death. Interestingly, Ba/F3 cells expressing Jak2 V617F mutant induced rapid tumorigenesis in nude mice, leading to rapid death. Whereas an injection of Ba/F3 cells expressing wild-type Jak2 had no effect, an injection of Ba/F3 cells expressing Jak2 V617F mutant promptly invaded and spread into various distinct organs, such as the liver and spleen. Strikingly, Jak2 inhibitor, AG490 potently inhibited cytokine-independent cell growth induced by the Jak2 V617F mutant. Also, treatment with AG490 effectively delayed Jak2 V617F mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo suggest that Jak2 harboring V617F mutation is a potent oncogene able to promote cell transformation and tumorigenesis.
AB - The somatic Jak2 mutation (V617F) was identified in most patients with polycythemia vera (PV). Here, we show that the activating Jak2 V617F mutant completely protected Ba/F3 cells from cytokine withdrawal-induced apoptotic cell death. Interestingly, Ba/F3 cells expressing Jak2 V617F mutant induced rapid tumorigenesis in nude mice, leading to rapid death. Whereas an injection of Ba/F3 cells expressing wild-type Jak2 had no effect, an injection of Ba/F3 cells expressing Jak2 V617F mutant promptly invaded and spread into various distinct organs, such as the liver and spleen. Strikingly, Jak2 inhibitor, AG490 potently inhibited cytokine-independent cell growth induced by the Jak2 V617F mutant. Also, treatment with AG490 effectively delayed Jak2 V617F mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo suggest that Jak2 harboring V617F mutation is a potent oncogene able to promote cell transformation and tumorigenesis.
KW - Anti-apoptosis
KW - Jak2
KW - Polycythemia vera (PV)
KW - Tumorigenesis
KW - V617F
UR - http://www.scopus.com/inward/record.url?scp=67349275711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349275711&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2009.03.011
DO - 10.1016/j.intimp.2009.03.011
M3 - Article
C2 - 19327411
AN - SCOPUS:67349275711
SN - 1567-5769
VL - 9
SP - 870
EP - 877
JO - International Immunopharmacology
JF - International Immunopharmacology
IS - 7-8
ER -